JLK (https://www.jlkgroup.com/), a leading medical AI company, has
announced the acceleration of its U.S. market entry with its
AI-based stroke diagnosis solutions. The Korean company with
world-class AI technology for stroke diagnosis, is now accelerating
its entry into the U.S. market.
As the first medical AI company to be listed on
the Korean stock exchange, JLK is renowned for its world-class
technology in AI stroke diagnosis solutions. The company offers a
comprehensive suite of 11 AI solutions for stroke diagnosis,
including five CT-based and six MRI-based solutions under the
MEDIHUB STROKE brand, which are gaining traction in the U.S.
market.
Stroke is one of the most frequently
misdiagnosed diseases. According to a study by Johns Hopkins
University, the misdiagnosis rate for strokes in the United States
is 17.5%. This results in approximately 800,000 people suffering
from permanent disabilities and about 370,000 deaths annually.
JLK offers the world's only solution that
utilizes artificial intelligence to provide essential quantitative
values necessary for stroke diagnosis throughout the entire stroke
cycle. The AI data, which is deep-learned from CT and MRI images,
includes various stroke-related information such as the presence of
stroke, location of the lesion, size and volume, severity (risk
level), and the presence of blood flow abnormalities, which doctors
can use as biomarkers for stroke diagnosis.
The solution consists of JLK-DWI (cerebral
infarction type), JLK-LVO (large vessel occlusion), JLK-ICH
(intracerebral hemorrhage), JLK-PWI (cerebral perfusion), JLK-WMH
(cerebral white matter degeneration), JLK-CMB (cerebral
microbleeds), JLK-LAC (chronic lacunar infarction), JLK-UIA
(cerebral aneurysm), JLK-CTL (non-contrast large vessel occlusion),
JLK-CTI (early detection of cerebral infarction), and JLK-CTP
(cerebral CT perfusion).
This year, JLK has officially declared its
full-scale entry into the U.S. market with plans to submit FDA
applications for five stroke diagnosis AI solutions. The company
has already submitted its Large Vessel Occlusion (JLK-LVO)
detection solution and aims to secure at least one solution for
U.S. insurance reimbursement to begin billing in clinical
settings.
Last month, JLK also obtained FDA 510(k)
clearance for its AI prostate cancer diagnosis solution, MEDIHUB
Prostate. Leveraging the expertise gained from this approval, JLK
is poised to expedite additional FDA approvals for its stroke
solutions.
JLK anticipates synergy through its mobile
healthcare application, Snappy. Snappy integrates all 11 of JLK’s
stroke diagnosis AI solutions, enabling real-time sharing of
clinical and imaging information interpreted by AI, thus
facilitating collaborative efforts among physicians.
The company explains that with the dedicated
messenger function for medical staff, easy collaboration and quick
decision-making are possible, and it is advantageous for securing
the golden time for remote stroke patients, making it an optimized
platform for treating time-critical stroke patients in large areas
like the United States.
The medical AI industry is closely watching the
U.S. stroke AI market, which is expected to be reshaped into a
three-way competition among the U.S.-based Rapid AI
(www.rapidai.com), Israel's Viz.ai (www.viz.ai), and Korea's
JLK.
Although Rapid AI and Viz.ai are already
actively marketing in the United States, their solutions are
limited to CT scans. Therefore, it is expected that JLK's
comprehensive CT and MR solution will demonstrate its
competitiveness. Furthermore, there is a prevailing opinion that
JLK, currently valued at 185 million USD, will establish an equal
footing with Viz.ai, valued at 1.27 billion USD, and Rapid AI,
valued at 769 million USD, when it enters the U.S. market.
Moreover, AI in healthcare is drawing
significant attention for its potential to reduce treatment costs
and improve patient outcomes. A report from the Harvard School of
Public Health indicates that integrating AI in healthcare can
reduce treatment costs by up to 50% and improve patient outcomes by
up to 40%.
Feedback from the medical community about AI in
healthcare is overwhelmingly positive. According to a survey
conducted by the American Medical Association last year, the
majority of physicians believe that AI enhances diagnostic
capabilities (72%), improves clinical workflow (69%), and clinical
outcomes (61%), while reducing administrative burdens (54%),
suggesting a growing adoption rate of AI healthcare solutions.
11 types of AI solutions for the entire stroke
care cycle developed by JLK
Contact Information
PR Team, JLK Inc.
Myung Ki-Young, PR Team Leader
(kymyung@jlkgroup.com / +82-10-8266-2194)
Lee Jeong-Heon, Assistant Manager
(jhlee1@jlkgroup.com / +82-10-9123-6690)
Social Links
Blog: https://blog.naver.com/jlk_ai_no1
LinkedIn:
https://www.linkedin.com/company/jlk-inspection/
YouTube: https://www.youtube.com/@JLK_ai
Media Contact
Brand: JLK
Contact: PR Team
Email: kymyung@jlkgroup.com
Website: https://www.jlkgroup.com
SOURCE: JLK